Medication Monitor

Generic Name (Trade Name—Company)
January 1, 2011

Human papillomavirus (HPV) quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

Anal cancer, neoplasia indications added


Prevention of anal cancer and anal intraepithelial neoplasia (AIN) grades 1-3

The vaccine is now approved by FDA for prevention of anal cancer caused by HPV types 16 and 18 and prevention of AIN grades 1–3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16, and 18 in males and females 9 to 26 years of age. The vaccine was previously approved for prevention of cervical, vaginal, and vulvar cancers in females. The product was also licensed for prevention of genital warts in females and males.